NEWS COMMENTARY

TechAccel further invests in RNAi technology and launches RNAissance Ag with Danforth Center

Published:
January 25, 2019
Coverage:
Emerging Ecosystems in Agrifood and Health More...
Activities:
Investment
12744 thumb square
by Joshua Haslun and Laura Krishfield
Very important

TechAccel, a technology and venture development company, and the Donald Danforth Plant Science Center have announced the launch of RNAissance Ag, a startup that holds an exclusive license to technology to develop RNA interference (RNAi) molecules developed at the Danforth Center. RNAissance's goal is to develop sprayable pesticides with a low environmental impact. TechAccel has shown significant interest in RNAi, participating in GreenLight Biosciences' latest funding round as well as entering into a research collaboration with AgroSpheres to develop biopesticide delivery systems. Clients should take note of increased funding around RNAi developments while recognizing that challenges remain for scaling RNAi in agriculture applications.

For the original news article, click here .


Further Reading

ARCUS gene editing platform gains $100 million IPO from Precision BioSciences

News Commentary | March 18, 2019

Precision BioSciences will use the IPO (NASDAQ) to advance scaling and the development of clinical and preclinical treatments. The IPO plan follows significant deals signed with Gilead for hepatitis B virus treatments and with Servier to develop chimeric T cell therapies. Together, these deals ... Not part of subscription

Genome Editing

Technology | May 24, 2018

Tools like CRISPR and TALENs make specific changes to the DNA of plants, animals, and microorganisms without using foreign DNA. Not part of subscription

Canada's National Centre for Drug Research and Development begins partnership with startup Schrödinger on AI-powered drug discovery

News Commentary | June 11, 2018

The space for AI‑driven drug development is heating up, and the CNRD is jumping in with a focus on new therapeutic antibodies. It will collaborate with Schrödinger, a startup in the space of AI‑powered drug discovery, to try to speed up the CNRD's usual process for small‑molecule drug development. ... Not part of subscription